Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prokidney Corp. (PROK)
:PROK
Holding PROK?
Track your performance easily
PROK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.18 - $4.44
Previous CloseN/A
Volume58.77K
Average Volume (3M)502.35K
Market Cap
$481.32M
Enterprise Value$1.27B
Total Cash (Recent Filing)$20.56M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Apr 01, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding127,968,250
10 Day Avg. Volume550,128
30 Day Avg. Volume502,352
Standard Deviation0.23
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.65
Forecast
1Y Price Target
$3.00Price Target Upside80.72% Upside
Rating ConsensusHold
Number of Analyst Covering1
ProKidney News
PremiumCompany Announcements
ProKidney’s Progress in FDA Approval and Financial Health
PremiumCompany Announcements
ProKidney: Investor Update and Phase 3 Program ProgressBulls Say, Bears Say
Bulls Say
Financial StabilityCurrent cash balance funds operations into 2027.
Market PotentialRilparencel is a differentiated approach in diabetic CKD with blockbuster potential.
Regulatory ApprovalFDA confirmed that PROACT 1 could be sufficient to support a BLA submission and full approval.
Bears Say
Financial PerformanceTopline results for the PROACT 1 study are expected in 3Q27, beyond the company's current cash runway.
Market SentimentNeed for more de-risking data for the product to increase Street focus and shift sentiment.
Research And DevelopmentThe sample size of the most recent data from the REGEN-007 study is small.
---
Ownership Overview
Currently, No data available
---
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $1.18 and its highest was $4.44 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $481.32M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Apr 01, 2025 which is in 72 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.15.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 127,968,250 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Among the largest hedge funds holding Prokidney Corp.’s share is EntryPoint Capital, LLC. It holds Prokidney Corp.’s shares valued at 33K.
---
ProKidney Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (80.72% Upside)
$3.00 (80.72% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.09%
Trailing 12-Months
Company Description
Prokidney Corp.
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Month Forecast
Average Price Target
$3.00
▲(80.72% Upside)
Technical Analysis
Atossa Therapeutics
―
Curis
―
Fate Therapeutics
―
Kiniksa Pharmaceuticals
―
Rocket Pharmaceuticals
―
Xenon
―
Best Analysts Covering PROK
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-35.21%
reiterated a buy rating 5 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -35.21% per trade.
---